Title

Nelarabine: efficacy in the treatment of clinical malignancies

Document Type

Article

Publication Date

2006

Digital Object Identifier (DOI)

10.2217/14796694.2.4.441

Abstract

Nelarabine is a nucleoside analog prodrug of 9-beta-D-arabinofuranosylguanine. Nelarabine is indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma whose disease has not responded to, or has relapsed after treatment with, at least two chemotherapy regimens. Nelarabine was granted Orphan Medical Product Status in Europe in June 2005, and accelerated approval by the US FDA in October 2005. The most common adverse events associated with nelarabine are neurotoxic in nature and have been dose-limiting.

This document is currently not available here.

Share

COinS